M&T Bank Corp Alkermes Plc. Transaction History

M&T Bank Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 29, 2020	SELL	$13.31 - $19.41 $10,648 - $15,528	-800 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$13.06 - $21.24 $10,448 - $16,992	800 New	800 $11.5 Million
Q4 2018 Feb 01, 2019	SELL	$27.94 - $44.61 $145,511 - $232,328	-5,208 Closed	0 $0
Q3 2018 Nov 09, 2018	BUY	$38.6 - $46.12 $201,028 - $240,192	5,208 New	5,208 $221,000
Q2 2018 Aug 10, 2018	SELL	$40.56 - $51.36 $214,237 - $271,283	-5,282 Closed	0 $0
Q1 2018 May 04, 2018	BUY	$53.61 - $67.26 $68,245 - $85,621	1,273 Added 31.75%	5,282 $307,000
Q4 2017 Feb 06, 2018	BUY	$47.69 - $55.39 $191,189 - $222,058	4,009 New	4,009 $221,000
Q3 2017 Nov 13, 2017	SELL	$49.16 - $54.45 $350,756 - $388,500	-7,135 Closed	0 $0
Q2 2017 Aug 11, 2017	BUY	N/A	7,135	7,135 $413,000

375

166M

231K

158K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.42B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

Stay updated on M&T Bank Corp with notifications on news.